{
  "nctId": "NCT04341116",
  "briefTitle": "Study of TJ003234 (Anti-GM-CSF Monoclonal Antibody) in Subjects With Severe Coronavirus Disease 2019 (COVID-19)",
  "officialTitle": "A Phase 2/3, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Evaluate the Safety and Efficacy of TJ003234 in Subjects With Severe Coronavirus Disease 2019 (COVID-19)",
  "protocolDocument": {
    "nctId": "NCT04341116",
    "filename": "Prot_000.pdf",
    "label": "Study Protocol",
    "date": "2021-09-23",
    "uploadDate": "2023-02-02T19:55",
    "size": 1152560,
    "downloadUrl": "https://clinicaltrials.gov/api/v2/studies/NCT04341116/document/Prot_000.pdf",
    "hasProtocol": true,
    "hasSap": false,
    "hasIcf": false
  },
  "phase": [
    "PHASE2",
    "PHASE3"
  ],
  "studyType": "INTERVENTIONAL",
  "allocation": "RANDOMIZED",
  "interventionModel": "PARALLEL",
  "masking": "QUADRUPLE",
  "enrollmentInfo": {
    "enrollmentCount": 149,
    "enrollmentType": "ACTUAL"
  },
  "timeline": {
    "startDate": "2020-04-11",
    "completionDate": "2022-02-07",
    "primaryCompletionDate": "2022-02-07",
    "firstSubmitDate": "2020-04-04",
    "firstPostDate": "2020-04-10"
  },
  "eligibilityCriteria": {
    "criteria": "Inclusion Criteria:\n\n* Age: 18 years or older (including 18 years); male or female\n* Laboratory-confirmed SARS-CoV-2 or COVID-19 infection as determined by polymerase chain reaction (PCR) or other commercial or public health assay.\n* Bilateral lung infection confirmed by imaging.\n* Severe disease that meets one of the following conditions: (i) At rest, finger blood oxygen saturation ≤ 93% or PaO2/FiO2 ≤ 300 mmHg; (ii) Requiring non-invasive or invasive mechanical ventilation; OR (iii) Requiring high flow oxygen ≥ 15L/min\n* Hospitalized for no more than 5 calendar days at the time of screening\n\nExclusion Criteria:\n\n* Any previous and/or current clinically significant disease or condition that has not been stable within 3 months prior to enrollment, or acute illness, planned medical/ surgical procedure, or any trauma that occurred within 2 weeks prior to enrollment.\n* Chronic obstructive pulmonary disease (COPD) patients requiring inhaled corticosteroid, long-acting beta-adrenergic agonists, long-acting anticholinergics, or long-term oxygen therapy (Part 1 only).\n* Pulmonary interstitial disease, pulmonary alveolar proteinosis, and pulmonary granulomatosis.\n* Cardiovascular event in the 3 months prior to study drug administration: acute myocardial infarction or unstable angina pectoris, severe arrhythmia (multiple sources of frequent ventricular premature beat, ventricular tachycardia and ventricular fibrillation); New York Heart Association Classification (NYHA): Class III-Class IV.\n* Blood system disorders or routine blood analysis test abnormalities: Hemoglobin \\< 8 g/dL; Absolute neutrophil count (ANC) \\<1500 × 109/L; Platelets \\< 50 × 109/L.\n* Dependence on glucocorticoid treatment equivalent to methylprednisolone 2 mg/kg/ day or more or long-term use of anti-rejection or immunomodulatory drugs.\n* Subjects that have been on invasive mechanical ventilation for ≥120 hours at the time of dosing\n* Subjects that require ECMO.\n* Pregnant or breastfeeding females.",
    "healthyVolunteers": false,
    "sex": "ALL",
    "minimumAge": "18 Years",
    "stdAges": [
      "ADULT",
      "OLDER_ADULT"
    ]
  },
  "endpoints": {
    "primary": [
      {
        "measure": "Percentage of Subjects Alive and Free of Mechanical Ventilation Among Subjects Who Are Free of Mechanical Ventilation at Baseline",
        "description": "Free of mechanical ventilation was defined as proportion of subjects who scores 1 to 5 in the following 8-category ordinal scale.\n\n8, death; 7, ventilation in addition to extracorporeal membrane oxygen (ECMO), continuous renal replacement therapy (CRRT) or pressors; 6, intubation and mechanical ventilation; 5, non-invasive mechanical ventilation (NIV) or high-flow oxygen; 4, hospitalization with oxygen by mask or nasal prongs; 3. Hospitalization without oxygen supplementation; 2, limitation of activities, discharge from hospital; and 1, no limitation of activities, discharge from hospital.",
        "timeFrame": "Day 1 through Day 30"
      }
    ],
    "secondary": [
      {
        "measure": "Percentage of Recovery by Day 14",
        "description": "Sustained recovery in clinical status was defined as patients who have hospitalization without oxygen supplement or discharge from hospital.",
        "timeFrame": "Day 1 through Day 14"
      },
      {
        "measure": "Percentage of Subjects Recovered on Day 30",
        "description": "Sustained recovery in clinical status was defined as patients who have hospitalization without oxygen supplement or discharge from hospital.",
        "timeFrame": "Day 1 through Day 30"
      },
      {
        "measure": "All-cause Mortality Rate by Day 30",
        "description": "The percentage of subjects who deceased by any cause.",
        "timeFrame": "Day 1 through Day 30"
      },
      {
        "measure": "Time to Recovery Among Subjects Alive by Day 30",
        "description": "Time to sustained recovery",
        "timeFrame": "Day 1 through Day 30"
      },
      {
        "measure": "Length of Hospitalization",
        "description": "Duration of hospitalization",
        "timeFrame": "Day 1 through Day 30"
      }
    ],
    "other": []
  },
  "complexityMetrics": {
    "eligibilityCriteria": {
      "inclusionCount": 1,
      "exclusionCount": 1,
      "totalCount": 2
    },
    "endpoints": {
      "primaryCount": 1,
      "secondaryCount": 5,
      "otherCount": 0,
      "totalCount": 6
    },
    "studyDesign": {
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "isRandomized": true,
      "isMasked": true,
      "interventionModel": "PARALLEL"
    },
    "overallComplexityScore": 74,
    "complexityCategory": "Complex"
  },
  "collectionDate": "2025-09-21T22:34:08.287Z",
  "dataSource": "ClinicalTrials.gov API v2 - Mass Collection"
}